Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT-003 gene therapy single intravitreal injection in diabetic macular edema (dose-escalation and expansion I/II study)
CTR20233375Phase 2Active
- Sponsor
- Frontera Therapeutics
- Start
- Oct 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of FT-003 in diabetic macular edema (DME), sponsored by Frontera Therapeutics. Started Oct 2023; status: active.
02
Drugs
FT-003
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on CTR20233375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233375.